T-cell engagers Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines bispecific T-cell engagers for autoimmune disease, antibodies that bring a patient T cell next to a B cell or plasma cell so that the T cell removes it, a mechanism proven in cancer and now repurposed for lupus, myasthenia gravis and other B cell mediated disease. It tests how fast engagers turn early depletion data into approved, off-the-shelf alternatives to CAR-T, and which participants capture value among developers, large biopharma firms, manufacturers and payers.

UCB announced on 3 May 2026 the acquisition of Candid Therapeutics for up to USD 2.2 billion, with USD 2.0 billion upfront and USD 200 million tied to milestones. Candid was launched in September 2024 with a USD 370 million Series A, and in January 2026 it reported that cizutamig, a BCMA engager, had been given to 80 patients, half with autoimmune disease, and CND261, a CD20 engager, to more than 110 patients, with cytokine release syndrome in under 20% of patients and no neurotoxicity. The conclusion is that a company less than two years old was bought for a price near CAR-T acquisitions on the strength of depletion and tolerability data in about 60 autoimmune patients.

UCB also licensed ATG-201, a CD19 and CD3 engager, from Antengene in March 2026, and GSK paid USD 300 million upfront for a CD19 and CD20 engager from Chimagen for lupus. Cullinan Therapeutics, which pivoted to autoimmune disease in 2024, planned initial lupus and rheumatoid arthritis data for its CD19 and CD3 engager CLN-978 in the second quarter of 2026, using step-up dosing from 10 micrograms to 30 micrograms with 48 hours of monitoring. The conclusion is that at least four large or well funded groups are competing on CD19, CD20 and BCMA targets, and dosing convenience, including a subcutaneous route, will separate them.

Developers argue that engagers can reach larger patient groups than CAR-T, whose manufacturing limits it to a narrower population, and rheumatologists want at least 20% to 30% of patients in remission without background therapy with no more than grade 1 or 2 cytokine release. The conclusion is that engagers must show drug-free remission after repeated dosing to match CAR-T, which is the evidence still to come.

The brief treats T-cell engagers for autoimmunity as an accelerating category with a ten year horizon to 2036 and identifies which diseases scale first and what each means for developers, large biopharma firms and payers.

It is a focused 104-page decision brief for biopharma firms, payers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which diseases scale first and who captures value.

A bispecific antibody binds CD3 on a T cell at one arm and a B cell or plasma cell marker such as CD19, CD20 or BCMA at the other, which directs the T cell to kill the target cell.

Antibody design, cell line development and protein production follow established oncology methods, so manufacturing is far simpler than for cell therapy.

Dosing starts low and steps up to manage cytokine release, with in-hospital monitoring after the first target dose and a plan toward outpatient and subcutaneous use.

Uses are lupus, rheumatoid arthritis, myasthenia gravis, Sjögren disease and other B cell mediated diseases, including patients who failed rituximab or complement inhibitors.

The limits are durability after dosing stops, cytokine release and infection risk, and competition from CAR-T. The decade turns on whether repeat dosing gives drug-free remission.

The T-cell engagers for autoimmunity market, covering bispecific T-cell engagers in development and early use for autoimmune disease, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 0.05–0.1 billion in 2026 and is projected to reach USD 1.45–2.89 billion by 2036, at a CAGR of 40%.

The 2026 base rests on licensing, collaboration and acquisition related payments and early programme spending. Growth then follows Phase 2 read-outs, registrational trials and the first approvals.

The forecast is sensitive to remission data, safety with repeat dosing, payer coverage and competition from CAR-T. Regionally, North America leads on developers and trials, Europe on large firm buyers, and Asia-Pacific on sources of oncology engagers repositioned for autoimmune disease.

The base case assumes Phase 2 data confirm depletion and remission and the first approval arrives around 2030, giving the inflection in 2032. An accelerated case assumes strong early remission data and fast registrational trials, bringing the inflection to 2030 and lifting the 2036 value to the top of the range. A delayed case assumes relapse after dosing stops and safety limits, holding growth at the bottom of the range.

Growth drivers

• Refractory disease with limited options.
• Limits of CAR-T manufacturing and access.
• Early clinical data on B cell depletion and safety.
• Reuse of oncology antibodies across diseases.

Enablers

• Large biopharma collaborations.
• Developer and manufacturer partnerships.
• Public research funding.
• Established antibody manufacturing.

Restraints and barriers

• Durability after dosing stops.
• Competition from CAR-T and other B cell therapies.
• Cytokine release and infection risk.
• Funding constraints at developers.

The direction of T-cell engagers for autoimmunity is set by demand from rheumatology and neurology patients, regulation, new targets and formats, prescriber and payer adoption, and manufacturing cost.

The key participants in T-cell engagers for autoimmunity include Candid Therapeutics, Inc., UCB S.A., Cullinan Therapeutics, Inc., Antengene Corporation Limited, GSK plc, Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson and the other developers, large firms, suppliers, payers, societies, regulators and standards bodies listed by archetype below.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as T-cell engagers for autoimmunity mature.

T-cell engager developers such as Candid Therapeutics, Cullinan Therapeutics and Antengene lead the clinical programmes, while large biopharma and antibody firms, antibody manufacturing and tools suppliers, patient groups, payers and societies, regulators, and standards bodies shape how fast engagers reach patients. Competitive intensity is moderate in 2026 because several developers share the same targets and large firms are buying positions, and it rises as Phase 2 data separate the products and as CAR-T approvals reach the same patients.

Where value migrates.

In 2026 value sits with developers holding engager assets and early data, with large firms that license or acquire, and with antibody manufacturers. By 2032 it moves toward companies with remission data and approvals, because payers cover products that give remission with outpatient dosing. By 2036 it settles in integrated antibody and manufacturing platforms. Margins hold for products with durable remission and narrow for late followers.

The signals converge on deal activity ahead of controlled data. A USD 2.2 billion acquisition, a USD 300 million upfront licence and a further licence were announced within about two years, and several developers planned Phase 2 data in 2026. Each signal supports growth, and remission after dosing stops is still to be shown.

Structural limits include durability after dosing stops, cytokine release and infection risk, competition from CAR-T and funding constraints. The brief tracks Phase 2 remission read-outs, registrational trial starts, subcutaneous formats and cost per treatment course.

Lupus, rheumatoid arthritis and myasthenia gravis, then Sjögren disease and other B cell mediated diseases, then earlier lines of therapy are the expected order of development.